Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Non-injectable Insulin Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?
The non-injectable insulin market has witnessed robust expansion in recent years. It is anticipated to expand from $2.14 billion in 2025 to $2.35 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.9%. This historical growth can be linked to factors such as the rising incidence of diabetes, increasing patient preference for non-injectable treatment options, developments in insulin formulations, governmental programs supporting diabetes care, and greater understanding of diabetes complications.
The non-injectable insulin market is projected to experience substantial expansion over the upcoming years. This market is predicted to reach $3.41 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.8%. Key drivers for this anticipated growth include improvements in oral and inhalable insulin technologies, the adoption of digital health solutions, an increasing elderly demographic, the development of healthcare infrastructure in burgeoning markets, and tailored medical strategies for diabetes management. Significant trends anticipated during this period encompass oral insulin delivery methods, pulmonary insulin inhalers, patient-focused diabetes care, non-invasive monitoring and dosing techniques, and novel formulations designed to enhance bioavailability.
Get A Free Sample Report With In-Depth Market Insights:
Non-injectable Insulin Market Growth Catalysts And Demand Drivers
The escalating concerns of obesity and diabetes are projected to drive expansion within the non-injectable insulin market. Obesity is defined by an excessive build-up of body fat, typically stemming from an imbalance in calorie intake versus expenditure. Concurrently, diabetes mellitus, or simply diabetes, encompasses metabolic disorders marked by persistently elevated blood sugar. Non-injectable insulin offers a treatment for both diabetes and obesity, with the capacity to enhance disease management by overcoming obstacles to traditional insulin therapy, delivering potential advantages in weight control, and presenting more user-friendly treatment alternatives. As an illustration, in June 2023, the Institute for Health Metrics and Evaluation, a public health research institute based in the US, reported that more than half a billion individuals worldwide were afflicted with diabetes. This figure is projected to exceed double, reaching 1.3 billion people by 2050. Consequently, the increasing prevalence of obesity and diabetes is fueling the expansion of the non-injectable insulin market.
Non-injectable Insulin Market Segment Analysis Spotlighting Growth Areas
The non-injectable insulin market covered in this report is segmented –
1) By Insulin Type: Oral Insulin, Inhaled Insulin, Nasal Insulin, Buccal Or Sublingual Insulin, Transdermal Insulin
2) By Product: Pills, Sprays, Other Products
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Drug Stores
Subsegments:
1) By Oral Insulin: Oral Insulin Tablets, Oral Insulin Capsules, Enteric-Coated Oral Insulin, Nanoparticle-Based Oral Insulin
2) By Inhaled Insulin: Dry Powder Inhaled Insulin, Aerosolized Insulin, Pulmonary Insulin Delivery Systems
3) By Nasal Insulin: Nasal Spray Insulin, Nasal Gel Insulin, Nasal Powder Insulin
4) By Buccal Or Sublingual Insulin: Buccal Spray Insulin, Sublingual Insulin Films, Oral Mucosal Insulin Drops
5) By Transdermal Insulin: Insulin Patches, Microneedle-Free Transdermal Systems, Iontophoresis-Based Insulin Delivery
Non-injectable Insulin Market Trends Shaping Long-Term Demand
Leading companies operating in the non-injectable insulin market are prioritizing innovative advancements in drug delivery technologies, such as needle-free oral insulin spray, to enhance the lives of individuals managing their diabetes with multiple insulin injections. A needle-free insulin spray offers a painless and non-invasive alternative for regulating blood glucose, providing a convenient option as the doses can be administered directly into the mouth. For instance, in November 2023, NiedlFree Technologies, an India-based technology platform, launched Ozulin, an oral insulin spray. This oral insulin spray aims to offer a more accessible solution for people with diabetes, especially those who find traditional injectable insulin methods difficult. If approved, Ozulin holds the potential to significantly impact diabetics, by providing a more convenient and pain-free substitute for insulin injections.
Non-injectable Insulin Market Leading Companies: Who Holds The Strongest Market Presence?
Major companies operating in the non-injectable insulin market are Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca, Takeda Pharmaceutical, Abbott Laboratories, MannKind Corporation, Biocon Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Limited, Cipla Limited, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Wockhardt Limited, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd.
View The Full Non-injectable Insulin Market Report:
Non-injectable Insulin Market Regional Breakdown: Where Is Demand Concentrated?
North America was the largest region in the non-injectable insulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-injectable insulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
